The Latest Breaking News from William Blair

Despite Trump’s reassurance that he won’t strip Tesla of its subsidies, his tax bill has already hurt the company, raising questions about whether TSLA stock remains a safe investment.

As advancements in cancer treatment continue to evolve, the pursuit of more effective therapies for metastatic colorectal cancer remains a critical focus in the pharmaceutical industry. Cardiff Oncology, Inc. (NASDAQ:CRDF) on Tuesday released data from the ongoing CRDF-004 Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care (SoC) in…

Toast and Five Below lead five stocks with revenue growth of at least 20% near buy points.

Sarepta Therapeutics (NASDAQ:SRPT) shares plummeted on Friday following reports of a third patient death linked to its gene therapy pipeline this year, further clouding investor confidence despite the company’s recent efforts to provide clarity on its restructuring and FDA label plans.

Tesla will release its Q2 2025 earnings next week. While AI and CEO Elon Musk’s politics might take center stage, there are some other pressing issues that the company should address.

On Wednesday, the Centers for Medicare Medicaid Services (CMS) proposed a significant step toward broader adoption of renal denervation (RDN) by offering coverage for both radiofrequency (rfRDN) and ultrasound (uRDN) technologies for uncontrolled hypertension. This coverage would be granted under a Coverage with Evidence Development (CED) framework, requiring treatment within…

Tesla stock lost nearly 7% Monday after Elon Musk announced plans of launching the “America Party.” William Blair downgraded TSLA shares.

Wedbush analysts have an ambitious price target of $75 on Oklo’s stock.

Uber is bracing for Tesla's robotaxi launch while MercadoLibre plays an aggressive, Amazon-like role in Latin America. They lead five stocks near buy points in new flat bases.